Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 3 Lymphoma, Non-Hodgkin 2 Carcinoma, Basal Cell 2 Basal Cell Nevus Syndrome 2 Upper Tract Urothelial Carcinomas 1 Solid Tumors 1 Serous Ovarian Cancer 1 Recurrence 1 Postmenopausal Women With ER+ HER2- Primary Breast Cancer 1 Ovarian Neoplasms 1 Leukemia 1 Immunoglobulin Light-chain Amyloidosis 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Breast Neoplasms 1 Amyloidosis 1

Interventions

Bevacizumab 27 Leucovorin 23 Fluorouracil 22 Oxaliplatin 17 Irinotecan 15 Cetuximab 14 pembrolizumab 11 IFL protocol 11 Panitumumab 10 Folfox protocol 10 Capecitabine 10 Gemcitabine 7 adagrasib 5 Cisplatin 5 Carboplatin 5 Ramucirumab 4 Colonoscopy 4 veliparib 3 spartalizumab 3 selpercatinib 3 regorafenib 3 labetuzumab 3 durvalumab 3 conatumumab 3 cemiplimab 3 Pemetrexed 3 Paclitaxel 3 HMPL-013 3 Drug Therapy 3 5,11-methenyltetrahydrohomofolate 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Colonic Neoplasms × Drug Evaluation × Clear all

NCT05189171 2024-06-28

MODEL-CRC

Xilis, Inc.

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡